medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2021, Number 1

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2021; 37 (1)

Molecular study of the JAK2V617F mutation: Is it correctly indicated?

Fernández ML, Díaz ACA

Language: Spanish
References: 10
Page: 1-5
PDF size: 242.74 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Greer JP, Rodgers GM, Glader B, Arber DA, Means Alan F. List et al, editores. Wintrobe's Clinical Hematology. 14ed. Philadelphia: Wolters Kluwer; 2019.

  2. Concepción Fernández Y. Síndrome mieloproliferativo crónico. En: Macías Abraham CM, Garrote Santana H, Forrellat Barrios M, Svarch E, Agramonte Llanes OM, Serrano Mirabal J, et al. Enfermedades hematológicas. Diagnóstico y tratamiento. La Habana: Editorial Ciencias Médicas;2019: p.99-126.

  3. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. Jan 2008;22(1):14-22.

  4. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 19 May 2016;127(20):2391-405.Citado: PMID:27069254.

  5. Amor Vigil AM, Díaz Alonso CA, Garrote Santana H, Suárez González Y, Fernández Delgado N, Avila Cabrera OM, et al. Introducción del estudio molecular de la mutación V617F del gen JAK2 en neoplasias mieloproliferativas clásicas BCR-ABL negativas. Rev Cubana Hematol Inmunol Hemoter [Internet].2013 [acceso 16/10/2019];29(4). Disponible en: Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/86

  6. Lee E, Lee KJ, Park H, Chung JY, Lee M, Chang MH, et al. Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms. Ann Lab Med. Mar 2018;38(2):147-54.

  7. Perricone M, Palandri F, Ottaviani E, Angelini M, Bagli L, Bellesia E, et al. Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories. Oncotarget. 2017 May16;8(20):32608-17.

  8. Jang MA, Choi CW. Recent insights regarding the molecular basis of myeloproliferative neoplasms. Korean J Intern Med. 2020;35(1):1-11.

  9. Sieza Y, Di Camilo I, Mazziott L, Archuby ML, Riva ME, Orellano L. Distribución de mutaciones en JAK2, MPL y CALR en pacientes con sospecha de neoplasias mieloproliferativas crónicas Phi negativas provenientes de hospitales públicos de la provincia de Buenos Aires. HEMATOLOGÍA. May- Ago 2018; 22(2): 151-6.

  10. Tefferi A, Noe P, Hanson CA. Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms. J Mol Diagn. 2011 Sep;13(5):461-6.




2020     |     www.medigraphic.com